Drug Profile
Tritoqualine - OSE Immunotherapeutics
Alternative Names: OSE-1101Latest Information Update: 26 Sep 2016
Price :
$50
*
At a glance
- Originator Unknown
- Developer OSE Immunotherapeutics
- Class Anti-inflammatories; Antiallergics; Antipruritics; Hepatoprotectants; Isoquinolines; Small molecules
- Mechanism of Action Histamine H4 receptor agonists; Interleukin-8 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Cystic fibrosis
Most Recent Events
- 26 Sep 2016 Chemical structure information added
- 31 May 2016 Effimune has merged with OSE Pharma to form OSE Immunotherapeutics
- 24 Jun 2015 Suspended - Phase-I for Cystic fibrosis in France (unspecified route) (OSE Pharma Coverage Initiation Report, June 2015)